Residency · Indianapolis, IN
Sponsored by Indiana University School of Medicine
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
Lancet (London, England) · 2024 · 194 citations · Alan Breier
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.
JAMA psychiatry · 2024 · 149 citations · Alan Breier
Functional Outcomes Over the First Year After Moderate to Severe Traumatic Brain Injury in the Prospective, Longitudinal TRACK-TBI Study.
JAMA neurology · 2021 · 308 citations · Thomas McAllister
Cortical thickness across the lifespan: Data from 17,075 healthy individuals aged 3-90 years.
Human brain mapping · 2022 · 243 citations · Alan Breier
Increased mood disorder symptoms, perceived stress, and alcohol use among college students during the COVID-19 pandemic.
Psychiatry research · 2021 · 237 citations · Stephanie Strong
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.
The New England journal of medicine · 2021 · 278 citations · Alan Breier
National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome.
Neurology · 2021 · 267 citations · Thomas McAllister
Consensus review and considerations on TMS to treat depression: A comprehensive update endorsed by the National Network of Depression Centers, the Clinical TMS Society, and the International Federation of Clinical Neurophysiology.
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2025 · 53 citations · Susan Conroy